实验（四）孚尔根（Feulgen）整体染色法在研究胚囊中的应用

实验（四）孚尔根（Ｆｅｕｌｇｅｎ）整体染色法在研究胚囊中的应用胡适宜（北京大学生物系北京１００８７１）ＢＬＯＣＫＳＴＡＩＮＩＮＧＯＦＦＥＵＬＧＥＮＰＲＯＣＥＤＵＲＥＵＳＥＤＩＮＴＨＥＳＴＵＤＹＩＮＧＯＦＥＭＢＲＹＯＳＡＣＳ￥ＨｕＳｈｉ－ｙｉ（Ｄｅｐａ...     

评《植物进化生物学》一书

评《植物进化生物学》一书李林初（复旦大学生物系上海２００４３３）ＡＲＥＶＩＥＷＡＢＯＵＴ“ＰＬＡＮＴＥＶＯＬＵＴＩＯＮＡＲＹＢＩＯＬＯＧＹ”ＥＤＩＴＥＤＢＹＣＨＥＮＧＪＩＡＫＵＡＮＡＮＤＹＡＮＧＪＩ￥ＬｉＬｉｎｃｈｕ（ＤｅｐａｒｔｍｅｎｔｏｆＢｉｏｌ...     

鹿科动物血清LDH同工酶的比较分析

鹿科动物血清ＬＤＨ同工酶的比较分析ＡＣＯＭＰＡＲＡＴＩＶＥＡＮＡＬＹＳＩＳＯＮＴＨＥＳＥＲＵＭＬＤＨＩＳＯＺＹＭＥＳＩＮＤＥＥＲＳ￥ＷＡＮＧＹｕｎｌｉｎｇ（ＤｅｐａｒｔｍｅｎｔｏｆＢｉｏｌｏｇｙ,ＴｉａｎｊｉｎＮｏｒｍａｌＵｎｉｖｅｒｓｉｔｙ）ＬＵＢ...     

蓝藻原生质球渗透稳定剂的研究

蓝藻原生质球渗透稳定剂的研究郭厚良,陈勇,金传荫（武汉大学生物系,４３００７２）（中国科学院水生生物研究所,武汉４３００７２）ＡＳＴＵＤＹＴＯＴＨＥＳＴＡＢＩＬＩＺＥＲＳＩＳＯＬＡＴＩＮＧＯＦＢＬＵＥ－ＧＲＥＥＮＡＬＧＡＬＳＰＨＥＲＯＰＬＡＳＴＳ￥Ｇ...     

矩阵微商法在多元线性回归模型影响分析中的一个应用

本文给出了Ｂ（Σ）对Σ的微商,Ｂ（Ｚ）是扰动的多元线性回归模型未知参数阵Ｂ的最小二乘估计（ＬＳＥ）,Σ＾－１是扰动矩阵,定义了度量扰动影响的距离测度Ｒ１,对于一些特殊情况还给出了Ｒ１的简单计算式;最后的实例说明用Ｒ１来度量各个点对Ｂ的估计Ｂ的影响是行之有效的简洁的方法。     

植物胚胎发育后期富集(LEA)蛋白的研究进展

植物胚胎发育后期富集（ＬＥＡ）蛋白的研究进展汤学军傅家瑞（中山大学生命科学学院,广州５１０２７５）ＰＲＯＧＲＥＳＳＯＦＴＨＥＳＴＵＤＹＯＮＬＡＴＥＥＭＢＲＹＯＧＥＮＥＳＩＳＡＢＵＮＤＡＮＴ（ＬＥＡ）ＰＲＯＴＥＩＮＳＩＮＰＬＡＮＴＳＴａｎｇＸｕｅ－Ｊ...     

苏北麦田恶性杂草麦家公的生态习性研究

苏北麦田恶性杂草麦家公的生态习性研究钱希（江苏省国营黄海农场,响水县,２２４６２４）ＡＳＴＵＤＹＯＮＥＣＯＬＯＧＩＣＡＬＨＡＢＩＴＳＯＦＢＡＤＷＥＥＤＳＬＩＴＨＯＳＰＥＲＭＵＭＡＲＶＥＮＳＥＩＮＷＨＥＡＴＦＩＥＬＤＳＯＦＴＨＥＮＯＲＴＨＪＩＡＮＧＳＵ...     

生物技术生产生物可降解塑料PHB的前景

生物技术生产生物可降解塑料ＰＨＢ的前景谢安勇,宋艳茹（中国科学院植物研究所,北京１０００４４）ＰＲＯＳＰＥＣＴＯＦＰＲＯＣＵＣＩＮＧＰＨＢ,ＡＢＩＯＤＥＧＲＡＤＡＢＬＥＰＬＡＳＴＩＣＢＹＵＳＩＮＧＢＩＯＴＢＣＨＮＯＬＯＧＹ￥ＸｉｅＡｎ－ｙｏｎｇ;Ｓｏ...     

林下栽培西洋参的试验研究

林下栽培西洋参的试验研究袁崇文（贵州省植物园,贵阳５５０００４）ＳＴＵＤＹＯＮＥＸＰＥＲＩＭＥＮＴＯＦＡＭＥＲＩＣＡＮＧＩＮＳＥＮＧＣＵＬＴＵＲＥＵＮＤＥＲＴＨＥＦＯＲＥＳＴＬＡＮＤ￥ＹＵＡＮＣｈｏｎｇ一Ｗｅｎ（ＧｕｉｚｈｏｕＢｏｔａｎｉｃＧａｒｄｅ...     

STUDIES ON THE PATTERN OF MEGASPOROGENESIS AND MICROTUBULAR CYTOSKELETON CHANGES IN CYMBIDIUM SINENSE

ＳＴＵＤＩＥＳＯＮＴＨＥＰＡＴＴＥＲＮＯＦＭＥＧＡＳＰＯＲＯＧＥＮＥＳＩＳＡＮＤＭＩＣＲＯＴＵＢＵＬＡＲＣＹＴＯＳＫＥＬＥＴＯＮＣＨＡＮＧＥＳＩＮＣＹＭＢＩＤＩＵＭＳＩＮＥＮＳＥ￥Ｓ．Ｙ．ＺｅｅＸ．Ｌ．Ｙｅ（１ＢｏｔａｎｙＤｅｐａｒｔｍｅｎｔ,Ｕｎｉ...     

协方差阵扰动增长曲线模型中回归参数阵B的影响分析

本文利用协方差阵扰动模型讨论增长曲线模型回归参数阵B的影响分析,获得了扰动前后B的最小二乘估计关系式,同时还得到了度量扰动影响的广义Cook距离．     

Estimation of kinetic cell-cycle-related gene expression in G1 and G2 phases from immunofluorescence flow cytometry data

BACKGROUND: Flow cytometry of immunofluorescence and DNA content provides measures of cell-cycle-related gene expression (protein and/or epitope levels) for asynchronously growing cells. From these data, time-related expression through S phase can be directly measured. However, for G1, G2, and M phases, this information is unavailable. We present an objective method to model G1 and G2 kinetic expression from an estimate of a minimum biological unit of positive immunofluorescence derived from the distribution of specific immunofluorescence of mitotic cells. METHODS: DU 145 cells were stained for DNA, cyclin B1, and a mitotic marker (p105) and analyzed by flow cytometry. The cyclin B1 immunofluorescence (B1) distribution of p105-positive cells was used to model the B1 distribution of G2 and G1 cells. The G1/S and S/G2 interface measurements were used to calculate expression in S phase and test the validity of the approach. RESULTS: B1 at S/G2 closely matched the earliest modeled estimate of B1 in G2. B1 increased linearly through G1 and S but exponentially through G2; mitotic levels were equivalent to the highest G2 levels. G1 modeling of B1 was less certain than that of G2 due to low levels of expression but demonstrated general feasibility. CONCLUSIONS: By this method, the upper and lower bounds of cyclin B1 expression could be estimated and kinetic expression through G1, G2, and M modeled. Together with direct measurements in S phase, expression of B1 throughout the entire cell cycle of DU 145 cells could be modeled. The method should be generally applicable given model-specific assumptions.     

Cell cycle specific changes in the human cyclin B1 gene regulatory region as revealed by response to trichostatin A

The human cyclin Bl gene is cell cycle regulated with maximal activity during G(2)/M. We examined the role of histone deacetylation in cyclin Bl regulation using the histone deacetylase inhibitor trichostatin A (TSA). TSA treatment (100 ng/ml) of NIH3T3 cells containing the luciferase reporter construct pCycB(-287)-LUC caused an increase in promoter activity in G(0) and G(1) but no significant change in G(2). Removal of upstream sequences including an E-box and Sp1 site eliminated the TSA induced increase in G(0) and G(1), and caused a decrease in promoter activity during S and G(2). Promoter activity increased only 2-fold following TSA treatment of G(0) cells containing the construct pCycB(MUT-E-Box)-LUC with an E-box mutation, and a decrease in activity was detected during G(2). We conclude that histone deacetylation contributes to the repression of cyclin B1 expression in G(0) and G(1), and that this mechanism requires, in part, the E-box. TSA reduction of cyclin B1 promoter activity in G(2), however, involves sequences within the first 119 bp. A working model for cyclin B1 regulation is provided.     

Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons

Botulinum neurotoxins (BoNTs) target presynaptic nerve terminals by recognizing specific neuronal surface receptors. Two homologous synaptic vesicle membrane proteins, synaptotagmins (Syts) I and II, bind toxins BoNT/B and G. However, a direct demonstration that Syts I/II mediate toxin binding and entry into neurons is lacking. We report that BoNT/B and G fail to bind and enter hippocampal neurons cultured from Syt I knockout mice. Wild-type Syts I and II (but not Syt I loss-of-function toxin-binding domain mutants) restored binding and entry of BoNT/B and G in Syt I–null neurons, thus demonstrating that Syts I/II are protein receptors for BoNT/B and G. Furthermore, mice lacking complex gangliosides exhibit reduced sensitivity to BoNT/G, and binding and entry of BoNT/A, B, and G into hippocampal neurons lacking gangliosides is diminished. These data suggest that gangliosides are the shared coreceptor for BoNT/A, B, and G, supporting a double-receptor model for these three BoNTs for which the protein receptors are known.     

Lysophospholipids control integrin-dependent adhesion in splenic B cells through G(i) and G(12)/G(13) family G-proteins but not through G(q)/G(11)

Integrin-mediated adhesion is a crucial step in lymphocyte extravasation and homing. We show here that not only the chemokines CXCL12 and CXCL13 but also the lysophospholipids sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) enhance adhesion of murine follicular and marginal zone B cells to ICAM-1 in vitro. This process involves clustering of integrin LFA-1 and is blocked by pertussis toxin, suggesting that G(i) family G-proteins are involved. In addition, lysophospholipid-induced adhesion on ICAM-1 depends on Rho and Rhokinase, indicative of an involvement of G(12)/G(13), possibly also G(q)/G(11) family G-proteins. We used G(12)/G(13)- or G(q)/G(11)-deficient B cells to study the role of these G-protein families in lysophospholipid-induced adhesion and found that the pro-adhesive effects of LPA and S1P are completely abrogated in G(12)/G(13)-deficient marginal zone B cells, reduced in G(12)/G(13)-deficient follicular B cells, and normal in G(q)/G(11)-deficient B cells. We also show that loss of lysophospholipid-induced adhesion results in disinhibition of migration in response to the follicular chemokine CXCL13, which might contribute to the abnormal localization of splenic B cell populations observed in B cell-specific G(12)/G(13)-deficient mice in vivo. Taken together, this study shows that lysophospholipids regulate integrin-mediated adhesion of splenic B cells to ICAM-1 through G(i) and G(12)/G(13) family G-proteins but not through G(q)/G(11).     

The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters

As novel SARS-CoV-2 variants continue to emerge, it is critical that their potential to cause severe disease and evade vaccine-induced immunity is rapidly assessed in humans and studied in animal models. In early January 2021, a novel SARS-CoV-2 variant designated B.1.429 comprising 2 lineages, B.1.427 and B.1.429, was originally detected in California (CA) and it was shown to have enhanced infectivity in vitro and decreased antibody neutralization by plasma from convalescent patients and vaccine recipients. Here we examine the virulence, transmissibility, and susceptibility to pre-existing immunity for B 1.427 and B 1.429 in the Syrian hamster model. We find that both variants exhibit enhanced virulence as measured by increased body weight loss compared to hamsters infected with ancestral B.1 (614G), with B.1.429 causing the most marked body weight loss among the 3 variants. Faster dissemination from airways to parenchyma and more severe lung pathology at both early and late stages were also observed with B.1.429 infections relative to B.1. (614G) and B.1.427 infections. In addition, subgenomic viral RNA (sgRNA) levels were highest in oral swabs of hamsters infected with B.1.429, however sgRNA levels in lungs were similar in all three variants. This demonstrates that B.1.429 replicates to higher levels than ancestral B.1 (614G) or B.1.427 in the oropharynx but not in the lungs. In multi-virus in-vivo competition experiments, we found that B.1. (614G), epsilon (B.1.427/B.1.429) and gamma (P.1) dramatically outcompete alpha (B.1.1.7), beta (B.1.351) and zeta (P.2) in the lungs. In the nasal cavity, B.1. (614G), gamma, and epsilon dominate, but the highly infectious alpha variant also maintains a moderate size niche. We did not observe significant differences in airborne transmission efficiency among the B.1.427, B.1.429 and ancestral B.1 (614G) and WA-1 variants in hamsters. These results demonstrate enhanced virulence and high relative oropharyngeal replication of the epsilon (B.1.427/B.1.429) variant in Syrian hamsters compared to an ancestral B.1 (614G) variant.     

The CholecystokininB Receptor Is Coupled to Two Effector Pathways Through Pertussis Toxin-Sensitive and -Insensitive G Proteins

Previous binding studies have suggested the existence of two affinity states for type B cholecystokinin receptors (CCK(B)R), which could correspond to different coupling states of the receptor to G proteins. To test this hypothesis, we have further investigated signal transduction pathways coupled to rat CCK(B)R stably transfected in Chinese hamster ovary cells. We show that CCK(B)R are coupled to two distinct transduction pathways involving two different G proteins, a pertussis toxin-insensitive/phospholipase C pathway leading to the production of inositol phosphate and arachidonic acid, and a pertussis toxin-sensitive/phospholipase A2 pathway leading to the release of arachidonic acid. We further demonstrate that the relative degree of activation of each effector pathway by different specific CCK(B)R agonists is the same, and that a specific CCK(B)R antagonist, RB213, can differentially antagonize the two signal transduction pathways elicited by these agonists. Taken all together, these data could be explained by the recently proposed theory assuming that the receptor can exist in a three-state model in which two active conformations corresponding to the complex formed by the receptor with two different G proteins coexist. According to this model, agonists or antagonists could recognize preferentially either conformation of the activated receptor, leading to variable behavior in a system containing a single receptor type.     

Sphingosine 1-phosphate activates nuclear factor-kappa B through Edg receptors. Activation through Edg-3 and Edg-5, but not Edg-1, in human embryonic kidney 293 cells.

Sphingosine 1-phosphate (S1P) exerts a variety of actions as a second messenger or as an agonist that binds to one or more members of the Edg family of G protein-coupled receptors. By using human embryonic kidney 293 cells, we show that S1P activates nuclear factor-kappa B (NF-kappa B) in a receptor-dependent fashion. Edg-3 and Edg-5, which are coupled to G(i), G(q), and G(13), affect activation of NF-kappa B, whereas Edg-1, which is coupled to G(i) alone, does not. We find that the activation of NF-kappa B requires protein kinase C and Ca(2+), probably downstream of G(q), but that the activation of Rho alone by S1P, whether through G(q) or G(13), does not translate into the activation of NF-kappa B. G beta gamma has little effect of its own but potentiates the activation of NF-kappa B achieved through other G proteins. We conclude that the activation of NF-kappa B by S1P is a receptor-mediated process that relies primarily on the activation of a phospholipase C by G(q) and secondarily on effector regulation through other G proteins.     

Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel

The genetic disease cystic fibrosis (CF) is caused by loss of function of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. Two CF mutants, G551D and G1349D, affect equivalent residues in the highly conserved LSGGQ motifs that are essential components of the ATP-binding sites of CFTR. Both mutants severely disrupt CFTR channel gating by decreasing mean burst duration (MBD) and prolonging greatly the interburst interval (IBI). To identify small molecules that rescue the gating defects of G551D- and G1349D-CFTR and understand better how these agents work, we used the patch clamp technique to study the effects on G551D- and G1349D-CFTR of phloxine B, pyrophosphate (PP(i)), and 2'-deoxy ATP (2'-dATP), three agents that strongly enhance CFTR channel gating. Phloxine B (5 microm) potentiated robustly G551D-CFTR Cl- channels by altering both MBD and IBI. In contrast, phloxine B (5 microm) decreased the IBI of G1349D-CFTR, but this effect was insufficient to rescue G1349D-CFTR channel gating. PP(i) (5 mm) potentiated weakly G551D-CFTR and was without effect on the G1349D-CFTR Cl- channel. However, by altering both MBD and IBI, albeit with different efficacies, 2'-dATP (1 mm) potentiated both G551D- and G1349D-CFTR Cl- channels. Using the ATP-driven nucleotide-binding domain dimerization model of CFTR channel gating, we suggest that phloxine B, PP(i) and 2'-dATP alter channel gating by distinct mechanisms. We conclude that G551D- and G1349D-CFTR have distinct pharmacological profiles and speculate that drug therapy for CF is likely to be mutation-specific.